Effects of memantine and galantamine on cognitive performance in aged rhesus macaques.

Jay S. Schneider, Elsa Y. Pioli, Yang Jianzhong, Qin Li, Erwan Bezard
Neurobiology of Aging. 2013-04-01; 34(4): 1126-1132
DOI: 10.1016/j.neurobiolaging.2012.10.020

Read on PubMed

1. Neurobiol Aging. 2013 Apr;34(4):1126-32. doi:
10.1016/j.neurobiolaging.2012.10.020. Epub 2012 Nov 15.

Effects of memantine and galantamine on cognitive performance in aged rhesus

Schneider JS(1), Pioli EY, Jianzhong Y, Li Q, Bezard E.

Author information:
(1)Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson
University, Philadelphia, PA19107, USA.

Current pharmacotherapies for Alzheimer’s disease (AD) are focused on improving
performance of daily activities, personal care, and management of problematic
behaviors. Both memantine, a noncompetitive N-methyl-D-aspartate channel blocker
and galantamine, a selective acetylcholinesterase inhibitor, are currently
prescribed as symptomatic therapies for AD. However, drugs that progressed
directly from testing in rodent models to testing in AD patients in clinical
trials failed to demonstrate consistent effects on cognitive symptoms.
Considering the lack of nonhuman primate data on the effects of memantine and
galantamine alone or in combination on cognitive dysfunction in aged nonhuman
primates, the present study examined how closely data derived from aged nonhuman
primates reflects data obtained in humans. Mild beneficial effects on aspects of
cognitive performance in aged primates were found, in general agreement with the
human clinical experience with these drugs but in contrast to the more positive
effects reported in the rodent literature. These data suggest that the nonhuman
primate might have more predictive validity for drug development in this area
than comparable rodent assays.

Copyright © 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.neurobiolaging.2012.10.020
PMID: 23158762 [Indexed for MEDLINE]

Know more about